Excellent response of cetuximab plus chemotherapy after pembrolizumab monotherapy in metastatic hypopharyngeal cancer: A case report

Patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) typically have an unfavorable prognosis, with a median survival of only 6 to 15 months in most studies. In cases other than local relapse or oligometastases, systemic therapy plays the dominant role. The choice of re...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Anh Tuan Pham, Thang Huu Nguyen, Thai Hong Le, Toan Khanh Phan, Anh Phuong Nguyen, Ngoc Minh Le, Thao Thu Vu
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Elsevier 2025-03-01
Cyfres:	Current Problems in Cancer: Case Reports
Pynciau:	Head and neck squamous cell carcinoma Metastatic hypopharyngeal cancer Cetuximab plus chemotherapy Pembrolizumab
Mynediad Ar-lein:	http://www.sciencedirect.com/science/article/pii/S2666621924000607
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!